Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Leutz

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmacopsychiatry|October 24, 2003
Cholesterol modulates amyloid beta-peptide's membrane interactionsGunter P Eckert, Christopher Kirsch, Steffen Leutz, et al.
Journal of Molecular Neuroscience : MN|June 13, 2002
Reduction of trophic support enhances apoptosis in PC12 cells expressing Alzheimer's APP mutation and sensitizes cells to staurosporine-induced cell deathSteffen Leutz, Barbara Steiner, Celio A Marques, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 3, 2025
Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind StudyMonica Luque, Kristina Zhelyazkova, Laxmikant Vashishta, et al.
Expert Opinion on Investigational Drugs|May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adultsMonika Tomaszewska-Kiecana, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Investigational Drugs|May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adultsAnel Pretorius, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Biological Therapy|July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisSteven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy|June 13, 2025
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degenerationHansjürgen Agostini, Kristine Baumane, Vilma Jūratė Balčiūnienė, et al.
Expert Opinion on Biological Therapy|July 23, 2025
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosisMamuka Lortkipanidze, Tobie de Villiers, Grzegorz Kania, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2025
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group StudyChris Wynne, Ulrike Lorch, Edrich Krantz, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmacopsychiatry|October 24, 2003
Cholesterol modulates amyloid beta-peptide's membrane interactionsGunter P Eckert, Christopher Kirsch, Steffen Leutz, et al.
Journal of Molecular Neuroscience : MN|June 13, 2002
Reduction of trophic support enhances apoptosis in PC12 cells expressing Alzheimer's APP mutation and sensitizes cells to staurosporine-induced cell deathSteffen Leutz, Barbara Steiner, Celio A Marques, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 3, 2025
Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind StudyMonica Luque, Kristina Zhelyazkova, Laxmikant Vashishta, et al.
Expert Opinion on Investigational Drugs|May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adultsMonika Tomaszewska-Kiecana, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Investigational Drugs|May 13, 2025
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adultsAnel Pretorius, Felicitas Bullo, Lukasz Jaskiewicz, et al.
Expert Opinion on Biological Therapy|July 12, 2023
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisSteven R Feldman, Nataliya Reznichenko, Fausto Berti, et al.
Expert Opinion on Biological Therapy|June 13, 2025
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degenerationHansjürgen Agostini, Kristine Baumane, Vilma Jūratė Balčiūnienė, et al.
Expert Opinion on Biological Therapy|July 23, 2025
A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosisMamuka Lortkipanidze, Tobie de Villiers, Grzegorz Kania, et al.
Expert Opinion on Investigational Drugs|May 22, 2023
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adultsChristopher Wynne, Paul Hamilton, Kristi McLendon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2025
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group StudyChris Wynne, Ulrike Lorch, Edrich Krantz, et al.
Pageof 1